EUSOL vs. PDGF Dressing for Diabetic Foot Ulcers

March 19, 2026 updated by: Dr. SamiUllah, Services Hospital, Lahore

Comparison of EUSOL Dressing Versus Platelet Derived Growth Factor Dressing in Wound Contraction of Grade II Wagner Diabetic Foot Ulcers: A Randomized Controlled Trial

Diabetic foot ulcers are a major cause of morbidity and amputation. This randomized controlled trial will compare the efficacy of a traditional antiseptic dressing (EUSOL) with a modern biologic dressing containing Platelet-Derived Growth Factor (PDGF) in promoting wound contraction. The study aims to determine if PDGF dressing leads to better healing outcomes in patients with Grade II Wagner diabetic foot ulcers.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

120

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Pakistan
    • Punjab Province
      • Lahore, Punjab Province, Pakistan, 54000
        • Services Institute of Medical Sciences

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Diagnosis of diabetes mellitus.
  • Presence of a Grade II Wagner diabetic foot ulcer (penetrating to subcutaneous tissue, without involvement of tendon, bone, or joint).
  • Ulcer size less than 6 x 6 cm at baseline.

Exclusion Criteria:

  • Uncontrolled diabetes
  • Malnourished (BMI less than 20)
  • HB less than 10
  • ABPI less than 0.9
  • Immunosuppression therapy
  • Patients with malignancy or uncontrolled cardiopulmonary, neurological, or psychiatric disease.
  • Severe active infection

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: EUSOL Group
Procedure: EUSOL Dressing
Daily dressing with freshly prepared Edinburgh University Solution of Lime (EUSOL) applied to the ulcer after standard debridement and cleansing.
Active Comparator: PDGF Group
Procedure: Platelet-Derived Growth Factor (PDGF) Dressing
PDGF-based topical preparation applied to the ulcer surface every fourth day, covered by a secondary dressing. Interim dressing changes used normal saline only.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of patients achieving wound contraction.
Time Frame: 4 weeks
Wound healing will be defined as the achievement of at least a 50% reduction in ulcer area from baseline after four weeks of treatment. Ulcer area will be calculated as maximum length multiplied by maximum width.
4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Services Hospital, Lahore

Collaborators

Services Institute of Medical Sciences, Pakistan

Investigators

  • Study Director: Awais Amjad Malik, MBBS, FCPS, Services Institute of Medical Sciences

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2020

Primary Completion (Actual)

December 31, 2025

Study Completion (Actual)

January 10, 2026

Study Registration Dates

First Submitted

March 19, 2026

First Submitted That Met QC Criteria

March 19, 2026

First Posted (Actual)

March 25, 2026

Study Record Updates

Last Update Posted (Actual)

March 25, 2026

Last Update Submitted That Met QC Criteria

March 19, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • RCT28SIMS

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetic Wound

Clinical Trials on EUSOL Dressing

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bangladesh

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe